Poster Abstracts • OFID 2017:4 (Suppl 1) • S115 posaconazole 0.25, terbinafine 0.06, and voriconazole 0.25. The patient underwent multiple surgical debridements and was treated over time with various antifungals (amphotericin B, micafungin, terbinafine, voriconazole, posaconazole), adjunct cytokines (IFN-γ, GM-CSF), and hyperbaric oxygen. However, the infection progressed into the right middle cranial fossa and meninges and the patient died 1 year after symptoms began. WES revealed a de novo splice-site mutation in STAT3 (c.1140-3C>G). cDNA sequencing showed nonsense mediated decay of the affected allele. No mutations in CARD9 or NADPH oxidase subunits were found; a DHR test was normal. The patient had normal blood myeloid cell subsets. Serum IgE level was elevated at 833 IU/ml. After stimulation with IL-6, the patient's memory CD4+ T cells and CD11c+ myeloid cells had reduced pSTAT3 levels compared with control cells. Cellular analysis of SOCS3, a STAT3-dependent downstream target, is underway to evaluate for functional STAT3 haploinsufficiency.
GFP-C5ar1
fl/fl mice succumbed to infection similar to C5ar1 KO mice. Mechanistically, C5ar1 does not mediate phagocyte recruitment in the infected kidney, but mediates neutrophil and macrophage fungal killing. The myeloid cell-type specific contribution is under investigation using S100a8-Cre tg GFP-C5ar1 fl/fl and Cx3cr1-Cre tg fl/fl mice as are the molecular mechanisms that promote C5ar1-dependent effector function.
Conclusion. C5ar1 is required for host survival during systemic candidiasis via regulating the antifungal effector function of phagocytes.
Disclosures. All authors: No reported disclosures. October 5, 2017: 12:30 PM Background. Patients with chronic mucocutaneous candidiasis (CMC) often develop azole-resistant Candida infections, making treatment difficult due to lack of oral antifungal drug options. VT-1598 is a novel broad-spectrum fungal CYP51 inhibitor designed for exquisite selectivity for the fungal target versus human CYP enzymes to circumvent classic azole side effects like drug-drug interactions. We report the efficacy of VT-1598 in the treatment of oral Candida infection (including by azole-resistant strains).
VT-1598 Inhibits the in vitro Growth of Mucosal

Methods. The in vitro MIC values of 28
Candida species isolated from patients with CMC due to AIRE mutations were tested against VT-1598 and fluconazole (FLC), using CLSI broth microdilution M27-S4. Plasma VT-1598 levels were measured using LC-MS/MS with electrospray ionization. Tongue fungal load was determined in IL-17 deficient Act1 -/-mice following sublingual C. albicans infection and once-daily oral treatment for 4 days with 25 mg/kg FLC or 3.2, 8, and 20 mg/kg VT-1598 starting 18 hours post-infection.
Results. Among 28 Candida isolates tested (22 C. albicans, three C. glabrata, and one each of C. utilis, C. dubiliensis, and C. krusei), 10 (36%) were not susceptible to FLC, based on CLSI breakpoints (>4 mg/ml). Remarkably, all 28 isolates were highly susceptible to VT-1598 (MIC 50 and MIC 90 , 0.06 and 0.125 mg/ml, respectively). Oral administration of VT-1598 led to mean drug levels in mouse plasma (2.0, 3.0, and 11 mg/ml at the low, mid, and high doses, respectively) that were higher than the MIC values. In vivo, VT-1598 was significantly more effective, compared with FLC, against FLC-susceptible and -resistant C. albicans, and led to elimination of fungal growth even at the lowest tested dose (3.2 mg/kg). After a 10-day washout period from the last dose, mice treated with VT-1598 did not have mucosal fungal growth, while mice treated with FLC had tongue fungal loads similar to vehicle control.
Conclusion. VT-1598 Background. Candida auris can colonize patients for a prolonged time causing life-threatening systemic infections. Replicative aging is the result of asymmetric division, which cause phenotypic changes between mother and daughter cells. We have previously published that older Cryptococcus neoformans and C. glabrata cells exhibit enhanced resistance to antifungals including fluconazole (FLC), five flucytosine (5FC), and sub-therapeutic amphotericin B (AMB). Additionally, they are more resistant to macrophage and neutrophil killing. This is relevant because older fungal cells accumulate in chronic infections. We hypothesized that older C. auris cells would also exhibit enhanced resistance to phagocytic cells and can alter drug resistance.
Methods. Magnetically labeled cells were grown for 10 generations (Gen) and then were isolated from daughter cells by magnetic column separation. Transmission electron microscopy (TEM) was performed to measure their cell wall thickness. Standard in vitro killing assays were performed with human neutrophils. In vivo virulence was compared in a Galleria injection model. Minimum inhibitory concentration to the antifungals was performed by CSLI methods. Rhodamine 6G (R6G), which is a fluorescent substrate for ABC-transporters, was used to measure efflux.
Results. In C. auris, 10 Gen old cells are larger than younger cells (0-3 Gen) and exhibit a thicker cell wall on TEM. The older cells are significantly more resistant to neutrophil killing (24.5% vs. 51.6%, P < 0.05 by paired t-test)). Eleven distinct isolates manifest variable virulence in the Galleria infection model (range 1-8 days). In C. auris, 10 Gen cells were significantly more virulent than 0 Gen cells (2 days vs. 4 days). Most (8 of 11) isolates were highly resistant to FLC and showed high efflux of R6G, whereas the three FLC sensitive isolates showed low efflux of R6G. Using these methods, we observed significant (1.5 to 2.0 fold, P < 0.05) increase in efflux activity of older cells in both sensitive and resistant isolates.
Conclusion. In C. auris replicative aging is associated with enhanced resistance to phagocytic killing, increased cell body size, and cell wall thickness. Aging also enhances efflux activity and thus may contribute even further to antifungal resistance.
Disclosures. All authors: No reported disclosures. Background. Cryptococcosis is an opportunistic fungal infection caused by both Cryptococcus neoformans and its sibling species, Cryptococcus gattii. Flucytosine (5FC) is one of the most widely used antifungals against Cryptococcus spp., yet very few studies have looked at the molecular mechanisms responsible for 5FC resistance in this pathogen.
Mechanisms of Flucytosine Resistance in Cryptococcus gattii
Methods. Eleven Cryptococcus gattii clinical isolates were selected based on differential 5FC susceptibility. All isolates underwent whole-genome sequencing and genomic differences in key genes involved in flucytosine metabolism were examined. Heterologous expression of FCY1 and spot sensitivity assays were performed to examine regions of interest based on genomic differences.
Results. Susceptibility assays and sequencing analysis revealed an association between a point mutation in cytosine deaminase (FCY1) and 5FC resistance in two C. gattii clinical isolates, B9322 and JS5. This mutation results in the replacement of arginine for histidine at position 29 and occurs within an unconserved stretch of amino acids. Heterologous expression of FCY1 and spot sensitivity assays demonstrate that the point mutation did not have any effect on FCY1 activities and was not responsible for 5FC resistance. Comparative sequence analysis further show that no amino acid changes were observed in either cytosine permeases (FCY2-4) or uracil phosphoribosyltransferase (UPRTase, encoded by FUR1) among 5FC resistant and 5FC susceptible C. gattii isolates.
Conclusion. Together, our work suggests that the mediator(s) of 5FC resistance in B9322 and JS5 is likely found either downstream of FUR1 or on disparate regulatory pathways that modulate flucytosine metabolism. These findings suggest clinical 5FC resistance in C. gattii may occur by a nontraditional mechanism(s).
Disclosures. Background. It has been observed in both civilian and military populations that high-energy events, such as tornados and blast injuries, have been associated with mucormycosis in otherwise immunocompetent patients. However, the effects of high shear force directly on fungal biology have not been explored. In order to elucidate the relationship between fungal mechanobiology and virulence, R. oryzae was exposed to high shear stress. Subsequent changes in virulence were measured in a validated fly model of mucormycosis. Finally, spores were simultaneously exposed to high shear forces and calcineurin inhibitors to determine whether this classical stress pathway was involved in changes in virulence in response to shear force.
Methods. 10 4 or 10 7 spores/ml of R. oryzae in 100 ml saline were either: (1) grown in static culture (CNTRL); (2) subjected to stirring at 1100 RPMs for 30-45 minutes (Tornadic Physical Shear Challenge, TPSC), or 3) subjected to TPSC in the presence of the calcineurin inhibitor tacrolimus (TPSCS + TAC). Wild-type flies were subsequently infected via dorsal thorax inoculation and monitored for survival over 7 days (n = 26 per group; performed in triplicate).
Results. Flies inoculated with R. oryzae exposed to high shear stress experienced significantly greater mortality compared with spores grown under static conditions (P < 0.001). Co-culture of spores grown under TPSC with tacrolimus (1 mg/ml) resulted in increased fly survival (P < 0.001). In fact, there was no significant difference between flies inoculated with spores subjected to high shear and TAC and spores grown under static conditions (P = 0.934).
Conclusion. Fungal exposure to high shear stress increases virulence. As calcineurin inhibition completely mitigated the effect of shear stress on Mucorales virulence, activation of the calcineurin stress response may play an important role in the mechanotransduction of shear stress to increased fungal virulence. October 5, 2017: 12:30 PM Background. The genus Rhizopus is the main cause of mucormycosis, a life-threatening infection that affects predominantly hosts with an impaired immune system. However, patients with severe trauma and burns, without prior immune deficiency, are also at increased risk of developing mucormycosis. Despite aggressive treatment that involves disfiguring surgery and antifungal therapy, mortality rates range from ~50 to 100%. Genetic manipulation of Rhizopus is critical for identifying fungal targets to develop more effective therapies. However, Rhizopus genetics are challenging because of lack of dominant selection markers, low efficiency of transformation, and rarity of chromosomal integration. Here we attempted to adapt the CRISPR/Cas9 technology to disrupt genes in R. delemar.
Methods. We used the Gibson cloning strategy to assemble all necessary elements of the CRISPR/Cas9 system in one plasmid using the pyrF as a selection marker. The targeted gene for disruption was a toxin-encoding gene with similarity to ricin. This disruption cassette was transformed using biolistic delivery system into R. delemar pyrF -strain (M16). Recombination events were studied by Southern blot analysis and ricin gene expression was analyzed by qRT-PCR. Furthermore, damage to alveolar epithelial cells (A549) and nasal epithelial cells (CCL30) was studied with 51 Cr-release assay.
Results. Five stable transformants were obtained with the CRISPR/Cas9 construct. Southern blot analysis and nucleotide sequencing confirmed a partial deletion of the ricin gene, in the region where the guide RNA was designed. Moreover, gene disruption was confirmed by abrogation of ricin expression in comparison to reference strains (wild type or mutant with the CRISPR/Cas9 plasmid void of ricin gene sequence). Finally, ricin-mutants showed significant reduction in damage to A549 cells and CCL30 cells when compared with the reference strains (20-30% reduction, P < 0.01 by t-test).
Conclusion. We have successfully adapted the CRISPR/Cas9 system to disrupt the ricin-like gene in R. delemar. This tool will enable us to better understand the pathogenesis of mucormycosis and ultimately aid in designing novel and more successful strategies to manage this lethal fungal infection.
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